

1 **Patterns and predictors of COVID-19 vaccine uptake among United States active duty**
2 **Service members, 2020-2022: Implications for future pandemics**

3 Erica Sercy^{1,2}, Laveta Stewart^{1,2}, Megan Clare Craig-Kuhn^{1,2}, Caryn Stern³, Brock Graham³,
4 Amber Michel^{1,2}, Edward Parmelee^{1,2}, Simon Pollett,^{1,2} Timothy Burgess¹, David R Tribble¹

5
6 ¹Infectious Disease Clinical Research Program, Department of Preventive Medicine and
7 Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland. ²Henry
8 M. Jackson Foundation for the Advancement of Military Medicine, Inc, Bethesda, Maryland.
9 ³Joint Trauma System, Joint Base San Antonio, San Antonio, Texas, USA.

10 **Corresponding author:**

11 David Tribble, MD, DrPH
12 Science Director, Infectious Disease Clinical Research Program
13 Professor, Department of Preventive Medicine and Biostatistics
14 Uniformed Services University of the Health Sciences
15 4301 Jones Bridge Rd, Bethesda, MD 20814
16 david.tribble@usuhs.edu, 240-694-2984

17 **Word count:** 2,928

18 **Conflict of interest:** The Uniformed Services University (USU) Infectious Diseases Clinical
19 Research Program (IDCRP), a US Department of Defense institution, and the Henry M. Jackson
20 Foundation (HJF) were funded under a Cooperative Research and Development Agreement to
21 conduct an unrelated phase III COVID-19 monoclonal antibody immunoprophylaxis trial
22 sponsored by AstraZeneca. The HJF, in support of the USU IDCRP, was funded by the

23 Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological,
24 and Nuclear Defense to augment the conduct of an unrelated phase III vaccine trial sponsored by
25 AstraZeneca. Both trials were part of the U.S. Government COVID-19 response. Neither is
26 related to the work presented here.

27 **Financial disclosure:** Support for this work was provided by the Infectious Disease Clinical
28 Research Program (IDCRP), a Department of Defense program executed through the Uniformed
29 Services University of the Health Sciences, Department of Preventive Medicine and Biostatistics
30 through a cooperative agreement with The Henry M. Jackson Foundation for the Advancement
31 of Military Medicine, Inc. (HJF). This project has been funded by the National Institute of
32 Allergy and Infectious Diseases, National Institutes of Health, under Inter-Agency Agreement
33 Y1-AI-5072, and the Defense Health Program, U.S. DoD, under award HU0001190002.

34

35

36 **Abstract**

37 **Introduction.** Vaccine mandates have been used to minimize the duty days lost and deaths
38 attributable to infectious disease among active duty Service members (ADSMs). In response to
39 the global COVID-19 pandemic, in August 2021, the United States Department of Defense
40 issued a COVID-19 vaccine mandate for all ADSMs. This study aimed to investigate COVID-19
41 vaccine uptake among the ADSM population, as well as factors associated with timing of
42 COVID-19 vaccine receipt.

43 **Methods:** This study included ADSMs on active duty between 1/1/2020-6/30/2022. Univariate
44 analyses investigated associations between demographic factors (age, sex, race, ethnicity, branch
45 of service, rank, state of residence) and COVID-19 diagnosis with the following outcomes: 1)
46 time to primary series initiation in relation to the DoD vaccine mandate, 2) time between doses
47 of the two-dose primary series, and 3) time between booster eligibility and receipt

48 **Results:** A total of 1,799,466 ADSMs were included, with 90% receiving ≥ 1 COVID-19 vaccine
49 dose during the study period and 77% initiating the primary series prior to the mandate. Over
50 80% of ADSMs received a complete primary series, with 96% of those adhering to the
51 recommended regimen. History of COVID-19 diagnosis was associated with later receipt of all
52 doses.

53 **Conclusions:** COVID-19 vaccine uptake was high among all ADSMs, with the majority
54 initiating the primary series before the mandate. The high vaccine uptake among ADSMs shown
55 here may be used as a guide to both military and civilian pandemic policy and outreach efforts
56 related to enhanced vaccine uptake.

57

58 **Introduction**

59 Historically, the United States (U.S.) military system has required specific vaccinations to aid in
60 combat readiness and preserve health.^{1,2} During the 1918 influenza pandemic, ~20-40% of U.S.
61 Army and Navy personnel experienced symptomatic illness, associated with ~8.7 million lost
62 duty days and 26,000 deaths.³ In response, an influenza vaccination requirement was issued in
63 1945 for all military personnel, and similar requirements have continued to be issued to cover the
64 vaccine schedule recommended by the U.S. Centers for Disease Control and Prevention (CDC)
65 and in response to emerging infectious agents.^{3,4} Vaccines currently required by the U.S.
66 Department of Defense (DoD) for all Service members prior to entry or at accession include
67 adenovirus, hepatitis A, hepatitis B, influenza, measles/mumps/rubella (MMR), meningococcal,
68 tetanus-diphtheria (Tdap), and varicella.^{1,4,5} Periodic administration of other vaccines is required
69 in specific risk-based circumstances, including yellow fever, typhoid, Japanese encephalitis, and
70 polio, as well as annual influenza vaccination.⁶ Prior to the COVID-19 pandemic, all vaccines
71 required by the DoD had full U.S. Food and Drug Administration (FDA) approval.^{4,5}

72 The first case of COVID-19 was reported in November 2019 in Wuhan, China, followed by
73 rapid spread worldwide.⁷ Development of a COVID-19 vaccine began in late March 2020,⁸
74 leading to the first Emergency Use Authorization (EUA) by the FDA in mid-December 2020 for
75 a two-dose vaccine series, with additional EUAs subsequently being granted to several other
76 vaccine products.⁹⁻¹¹ Between January 2020 and August 2021, there were ~190,000 COVID-19
77 cases among active duty and Reserve/Guard Service members.¹² By July 2021, even in the
78 absence of FDA approval, a large percentage (~67%) of the active duty population had received
79 at least one dose of a COVID-19 vaccine.¹³ Following the first FDA approval of a COVID-19
80 vaccine on 23 August 2021 (Pfizer),¹⁴ the DoD issued a mandate on 24 August 2021 that all

81 active duty Service members must be vaccinated against COVID-19 or face discharge to “protect
82 the health and readiness of the force.”¹⁵ In September 2021, the first EUA for a booster dose was
83 issued.¹⁶

84 Despite high levels of early uptake of the COVID-19 vaccine among active duty Service
85 members, several challenges to full vaccination have presented. In surveys of military personnel,
86 20-40% reported COVID-19 vaccine hesitancy, noting concerns about “short-term side effects,”
87 “long-term side effects,” “vaccine effectiveness,” “being infected with COVID-19 from the
88 vaccine,” “worry about misinformation/political agenda,” and “lack of trust in the
89 government.”¹⁷⁻¹⁹ In addition, because two of the three most commonly available vaccines in the
90 U.S. in the early pandemic comprised a two-dose series (Pfizer, Moderna), attrition after the first
91 dose led to incomplete vaccination: as of May 11, 2023, 81% of the general U.S. population had
92 received at least one dose, but only 70% completed a two-dose primary series.²⁰ To inform
93 preparedness plans for future vaccine-preventable infectious threats, this study aimed to describe
94 the patterns and predictors of COVID-19 vaccine receipt among active duty Service members in
95 the Military Health System (MHS).

96 **Methods**

97 *Study Population and Variables*

98 Data without personal identifiers were from the MHS Data Repository (MDR), a claims-based
99 centralized repository that includes healthcare data on all beneficiaries of the MHS, including
100 active duty Service members, Reserve/Guard members, veterans/retirees, and dependents. This
101 research received an exempt determination by the Uniformed Services University of the Health
102 Sciences Human Research Protection Program.

103 This study included active duty Service members and Reserve/Guard members on active duty
104 (collectively ADSMs) at any time in 1/1/2020-6/30/2022. Individuals were excluded if they had
105 missing age or age <17 or >65. Only ADSMs who received all doses from products with EUAs
106 in the U.S. (Pfizer, Moderna, Janssen/Johnson & Johnson) were included. Individuals were
107 excluded if they met any of the following conditions that suggested documentation error: 1) a
108 first recorded dose date prior to the EUA date (Pfizer: 12/11/2020; Moderna: 12/18/2020;
109 Janssen/Johnson & Johnson: 2/27/2021); 2) booster dates prior to the first booster EUA (Pfizer:
110 9/22/2021); 3) <17 days between primary series doses (Pfizer, Moderna); or 4) <5 months (150
111 days, Pfizer, Moderna) or <2 months (60 days, Janssen/Johnson & Johnson) between completion
112 of the primary series and the first booster (Supplementary Figure 1).

113 The following variables were collected on all individuals: demographics (age, sex, race,
114 ethnicity, branch of service, rank, state of residence), all COVID-19 vaccine doses (date,
115 manufacturer), and COVID-19 diagnosis (infection criteria met, diagnosis date). State of
116 residence was defined using permanent residence for Reserve/Guard members and assigned unit
117 location for individuals on active duty; residence was measured at COVID-19 diagnosis date for
118 those with infection during the study period and most recent address (end of study period or end
119 of active duty) for individuals with no COVID-19 diagnosis during the study period. COVID-19
120 diagnosis was defined as either lab confirmed, i.e., documented positive PCR or antigen test, or
121 using ICD-10-CM codes (Supplementary Table 1). The index date of infection was the first date
122 meeting either lab or ICD-10-CM criteria; for individuals with multiple COVID-19 diagnoses,
123 only the earliest diagnosis date was considered.

124 A high degree of collinearity was detected between state of residence and multiple other
125 variables (race, branch of service, rank) in the dataset. It is likely that much of the collinearity

126 between state of residence and branch of service is attributable to the differential presence of
127 military bases in each state (Supplementary Figure 2). Because previous studies have reported
128 wide geographic variation in COVID-19 waves, variants, and vaccination rates across the
129 U.S.,²¹⁻²³ it was determined that state of residence should be retained as a variable in the final
130 analyses. Therefore, to account for collinearity, findings are reported overall and stratified by
131 state of residence. Only results for select states with the largest ADSM populations are displayed
132 in the stratified analyses.

133 *Statistical Analyses*

134 Associations of demographics and COVID-19 diagnosis with the following outcomes were
135 examined: 1) initiation of the primary series in relation to the DoD COVID-19 vaccine mandate,
136 2) completion of a two-dose primary series in the manufacturer-recommended timeframe, and 3)
137 days between booster eligibility and receipt. Timing of primary series initiation was defined as
138 receipt of a first COVID-19 vaccine primary series dose prior to compared to after the DoD
139 mandate. Timing of primary series completion was defined as occurring within the period
140 recommended by the vaccine manufacturer (Pfizer or Moderna; ≤ 56 days between the first and
141 second dose) compared to late (> 56 days). An individual's booster eligibility date was defined as
142 the later of the following: 1) 22 September 2021 (the EUA for the first booster) or 2) the
143 completion date of the primary series plus 5 months (Pfizer or Moderna primary series) or 2
144 months (Janssen/Johnson & Johnson primary dose). Univariate associations with each outcome
145 were assessed in the population overall and stratified by state of residence using chi-square tests,
146 Mann-Whitney U tests, and unadjusted logistic or generalized linear regression modeling.
147 Adjusted regression analyses were not performed because of multicollinearity that remained in

148 multivariable models after stratifying by state of residence. All statistical analyses were
149 conducted using SAS Studio (SAS Institute, Inc., Cary, NC).

150 **Results**

151 The study population included 1,799,466 ADSMs. Most of the population was age 17-49 (98%),
152 male (82%), white (71%), non-Hispanic (83%), an enlisted-level Service member (83%), and in
153 the Army (39%), Navy (23%), or Air Force (22%) (Supplementary Table 2). The seven states
154 with the largest ADSM populations were California (12% of the full population), Texas (9%),
155 Virginia (8%), North Carolina (7%), Georgia (5%), Florida (5%), and Washington (4%). In the
156 full population, 23% of ADSMs received a complete primary COVID-19 vaccine series and at
157 least one booster, 61% received a complete primary series with no booster, 5% received an
158 incomplete primary series, and 10% had no record of receiving one of the three COVID-19
159 vaccine products evaluated here (Table 1). Florida (90%) and Virginia (90%) had the highest
160 percentages of individuals who received a complete primary series, followed by Washington
161 (86%), California (84%), North Carolina (83%), Texas (83%), and Georgia (82%) ($P < 0.0001$).

162 Among the 1,594,948 ADSMs who initiated a primary series, 77% initiated prior to the DoD
163 mandate (Figure 1 and Table 1). Primary initiation timing differed by state of residence, with
164 Washington (85%), Virginia (80%), and California (78%) having the highest percentages of
165 residents initiating prior to the mandate. Individual-level factors significantly associated with
166 initiation of the primary series prior to the mandate included older age (OR=2.46, 95% CI 2.38-
167 2.54), female sex (OR=1.04, 95% CI 1.03-1.05), American Indian or Alaska Native (OR=1.06,
168 95% CI 1.02-1.10), Asian or Pacific Islander (OR=2.02, 95% CI 1.98-2.05), or other (OR=1.34,
169 95% CI 1.32-1.37) race compared to white, Hispanic ethnicity (OR=1.03, 95% CI 1.02-1.04),
170 Coast Guard (OR=1.54, 95% CI 1.50-1.58) or Navy (OR=1.54, 95% CI 1.52-1.55) branch of

171 service compared to Army, and officer (OR=4.28, 95% CI 4.22-4.35) or warrant officer
172 (OR=2.03, 95% CI 1.96-2.10) rank compared to enlisted (Table 2 and Supplementary Table 3).
173 Black or African American (OR=0.75, 95% CI 0.74-0.76) race, Air Force (OR=0.88, 95% CI
174 0.87-0.89) or Marine Corps (OR=0.58, 95% CI 0.57-0.59) branch of service, and COVID-19
175 diagnosis prior to initiating the primary series (OR=0.55, 95% CI 0.54-0.55 for lab confirmed,
176 OR=0.51, 95% CI 0.50-0.52 for ICD-10-CM defined) were associated with lower odds of
177 initiating before the mandate. The higher odds of pre-mandate initiation for older ADSMs, Asian
178 or Pacific Islanders, and officer or warrant officers held across all states; likewise, the lower odds
179 of pre-mandate initiation for blacks or African Americans, those in the Marine Corps, and those
180 with a COVID-19 diagnosis prior to initiating the primary series held across all seven states
181 (Table 2 and Supplementary Table 4).

182 Among those ADSMs who completed a two-dose primary series, 96% received the second dose
183 within the recommended timeframe (Table 1). The percentage of ADSMs completing their
184 primary series in the recommended time differed significantly by state, ranging from a low of
185 95% in Texas to a high of 97% in Virginia, Florida, and Washington. Female sex (OR=1.04,
186 95% CI 1.02-1.06), Asian or Pacific Islander (OR=1.19, 95% CI 1.15-1.24), and other (OR=1.25,
187 95% CI 1.20-1.30) race compared to white, Air Force (OR=1.33, 95% CI 1.30-1.36), Coast
188 Guard (OR=1.07, 95% CI 1.02-1.13), Marine Corps (OR=1.17, 95% CI 1.14-1.20), and Navy
189 (OR=1.80, 95% CI 1.76-1.85) branch of service compared to Army, and officer (OR=1.44, 95%
190 CI 1.41-1.48) rank compared to enlisted had higher odds of completing the primary series in the
191 recommended timeframe (Supplementary Tables 3 and 5). Black or African American race
192 (OR=0.90, 95% CI 0.88-0.92) and a COVID-19 diagnosis between the first and second primary
193 doses (lab confirmed, OR=0.23, 95% CI 0.21-0.24; ICD-10-CM defined, OR=0.23, 95% CI

194 0.22-0.25) were associated with lower odds of completing the second primary dose in the
195 recommended time. The lower odds of primary series completion in the recommended time for
196 COVID-19 diagnosis between primary doses held across all seven states (Supplementary Tables
197 5 and 6).

198 Among ADSMs who completed a primary series and received at least one booster, the median
199 time between booster eligibility and receipt was 90 days (Table 1). This median time was
200 significantly different across states, ranging from 85 days in Texas to 98 days in California and
201 Washington. Individual factors associated with shorter time between eligibility and receipt
202 included older age (the older age group got their booster a mean of 18.78, 95% CI 17.96-19.59,
203 days before the younger group), female sex (5.93, 95% CI 5.53-6.33, days before males), other
204 race (0.81, 95% CI 0.16-1.47, day before whites), Coast Guard (6.72, 95% CI 5.71-7.73, days
205 before Army) branch of service, and officer (16.13, 95% CI 15.78-16.49, days before enlisted) or
206 warrant officer (7.86, 95% CI 6.71-9.01, days before enlisted) rank (Table 3 and Supplementary
207 Table 3). Factors associated with longer time between booster eligibility and receipt included
208 American Indian or Alaska Native race (4.23, 95% CI 2.58-5.87, days after whites), Hispanic
209 ethnicity (4.20, 95% CI 3.76-4.65, days after non-Hispanics), Air Force (0.69, 95% CI 0.28-1.10,
210 days after Army), Marine Corps (18.21, 95% CI 17.51-18.91, days after Army) and Navy (7.74,
211 95% CI 7.33-8.16, days after Army) branch of service, and COVID-19 diagnosis between
212 completion of the primary series and the booster (40.72, 95% CI 40.07-41.36, days after the no-
213 infection group for lab confirmed; 22.49, 95% CI 21.61-23.37, days after the no-infection group
214 for ICD-10-CM defined). The associations of older age and female sex with fewer days between
215 booster eligibility and receipt and the associations of COVID-19 diagnosis between the primary

216 series and booster with longer time between eligibility and receipt were consistent across all
217 states (Table 3 and Supplementary Table 7).

218 **Discussion**

219 In this study, which aimed to evaluate U.S. military deployment of the COVID-19 vaccine
220 during the pandemic, results showed that most of the ADSMs who initiated a COVID-19
221 primary series did so prior to the DoD vaccine mandate, at over three-fourths (77%) of the
222 population reported here. The mandate resulted in a further substantial increase, with 87% of the
223 population initiating by the end of December 2021 and 90% at the end of the study period
224 (Figure 1). This is higher than in the overall adult U.S. population, where ~78% of individuals
225 had received at least one vaccine dose by the end of the study period (30 June 2022).²⁰

226 Trends in vaccine uptake varied over time between the overall U.S. and ADSM populations.
227 Both groups showed a large spike in primary series initiation soon after the EUAs in January-
228 April 2021 (Figure 1).²⁰ However, initiation among ADSMs thereafter showed a single notable
229 spike after the DoD mandate in August 2021 (Figure 1). Trends in overall U.S. vaccine initiation
230 appeared to be more responsive to COVID-19 variant waves,²⁴ with later peaks in initiation
231 corresponding to the Delta (June-November 2021) and early Omicron (December 2021-February
232 2022) waves in the U.S.²⁵ The ADSM population did not show similar responses to these waves,
233 although the DoD mandate was issued during the Delta wave in the U.S., and so the peak in
234 initiation after the mandate may have been affected by both factors.

235 Some associations of demographic factors with vaccine timing outcomes were consistent across
236 all states, such as the increased odds of higher-ranking ADSMs initiating their primary series
237 before the mandate, completing their second dose in the recommended time, and receiving their

238 booster closer to their eligibility date. Additionally, COVID-19 diagnosis during a relevant
239 timeframe was consistently associated with less-favorable vaccine metrics. However, this delay
240 is consistent with CDC recommendations, stating that individuals should not receive a COVID-
241 19 vaccine during active COVID-19 disease and should delay their vaccine until after their
242 isolation period is over: 7-10 days after symptom onset or first positive test and up to 20 days for
243 those with severe illness.²⁶ The CDC additionally suggested during the early pandemic that
244 individuals consider delaying COVID-19 vaccination until 3 months after symptom onset or a
245 first positive test, in an effort to preserve vaccine supply and capitalize on natural immunity from
246 infection.²⁷

247 Other associations varied by state, likely reflecting complex factors that interact to influence
248 vaccination behavior, including differential vaccine messaging and deadlines within each branch
249 of service,²⁸ overall vaccine messaging and environment by state,²⁹⁻³¹ and requirements related
250 to deployment,³² among many other secular factors (e.g., issues with vaccine supply shortages in
251 certain regions).^{33,34}

252 In a complementary manuscript, Dullea et al. (unpublished observations) described demographic
253 factors in the ADSM population associated with completion of the COVID-19 primary vaccine
254 series after the DoD mandate compared to those who remained unvaccinated in 12/11/2020-
255 1/1/2022. Their findings showing an association between history of COVID-19 infection and
256 unvaccinated status mirror the findings reported here. Further, Dullea et al. found that ADSMs
257 who completed their series in response to the mandate were more likely to be black or African
258 American, Hispanic, male, or of officer rank compared to those who remained unvaccinated. As
259 our findings here reported that ADSMs who were black or African American, Hispanic, or male
260 were less likely to initiate their primary series pre-mandate, the Dullea et al. manuscript shows

261 that the DoD mandate “picked up” those individuals who did not initiate pre-mandate and
262 reduced disparities in vaccine status across demographic factors by the end of the observation
263 period, further emphasizing the effectiveness of the mandate among this population.

264 Limitations of COVID-19 vaccine data include highly variable vaccine availability and
265 eligibility for the primary series and boosters over the course of the pandemic. For example,
266 these analyses considered booster eligibility as the later of 22 September 2021 (the first booster
267 EUA) or 5 months after primary series completion. However, on 22 September 2021, the Pfizer
268 booster was recommended only for select high-risk individuals.³⁵ Therefore, most of the young,
269 healthy population included here was likely not recommended to receive a booster dose on this
270 date; however, to standardize analyses, this EUA date was utilized as the booster eligibility date
271 across the population. This likely resulted in overestimation of times between booster eligibility
272 and receipt.

273 **Conclusions**

274 Vaccine development during the COVID-19 pandemic proceeded at an extraordinarily rapid
275 pace, with EUAs issued only ~9 months after the official start of the pandemic. The DoD has
276 historically required select vaccines among ADSMs, but these requirements have applied to
277 vaccines with full FDA approval. The findings here showed that ADSMs were highly responsive
278 to seeking COVID-19 vaccination during the EUA period, prior to FDA approval. The DoD
279 COVID-19 vaccine mandate was subsequently successful at further raising the already high
280 coverage among ADSMs. Overall, although uptake differed significantly by branch of service,
281 rank, and state of residence, the data described here indicate an effective vaccine implementation
282 effort by the DoD during the COVID-19 pandemic, leading to COVID-19 vaccine coverage that

283 exceeded coverage in the civilian population, as well as earlier uptake than the overall U.S.
284 population.

285

286 **Acknowledgements**

287 Support for this work was provided by the Infectious Disease Clinical Research Program
288 (IDCRP), a Department of Defense program executed through the Uniformed Services
289 University of the Health Sciences, Department of Preventive Medicine and Biostatistics through
290 a cooperative agreement with The Henry M. Jackson Foundation for the Advancement of
291 Military Medicine, Inc. (HJF). This project has been funded by the National Institute of Allergy
292 and Infectious Diseases, National Institutes of Health, under Inter-Agency Agreement Y1-AI-
293 5072, and the Defense Health Program, U.S. DoD, under award HU0001190002.

294 **References**

- 295 1. Ratto-Kim S, Yoon IK, Paris RM, Excler JL, Kim JH, O'Connell RJ. The US military
296 commitment to vaccine development: A century of successes and challenges. *Front*
297 *Immunol.* 2018;9:1397.
- 298 2. Ho ZJM, Hwang YFJ, Lee JMV. Emerging and re-emerging infectious diseases:
299 Challenges and opportunities for militaries. *Mil Med Res.* 2014;1:21.
- 300 3. Byerly CR. The U.S. military and the influenza pandemic of 1918-1919. *Public Health*
301 *Rep.* 2010;125(Suppl 3):82-91.
- 302 4. Elliott BP, Chambers S. A historical analysis of vaccine mandates in the United States
303 military and its application to the COVID-19 vaccine mandate. *Vaccine.*
304 2022;40(51):7500-7504.
- 305 5. Yang YT, Reiss DR. Military Vaccinations. In: *Vaccine Law and Policy*. 1st ed. Springer
306 Cham; 2023:185-191.
- 307 6. Defense Health Agency Military Health System. Immunization healthcare division.
308 Published April 5, 2024. Accessed April 11, 2024. [https://health.mil/Military-Health-](https://health.mil/Military-Health-Topics/Health-Readiness/Immunization-Healthcare)
309 [Topics/Health-Readiness/Immunization-Healthcare](https://health.mil/Military-Health-Topics/Health-Readiness/Immunization-Healthcare)
- 310 7. Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic. *Acta Biomed.*
311 2020;91(1):157-160.
- 312 8. Le TT, Andreadakis Z, Kumar A, et al. The COVID-19 vaccine development landscape.
313 *Nat Rev Drug Discov.* 2020;19(5):305-306.

- 314 9. US Food & Drug Administration. FDA takes key action in fight against COVID-19 by
315 issuing emergency use authorization for first COVID-19 vaccine.
316 [https://www.fda.gov/news-events/press-announcements/fda-takes-key-action-fight-](https://www.fda.gov/news-events/press-announcements/fda-takes-key-action-fight-against-covid-19-issuing-emergency-use-authorization-first-covid-19)
317 [against-covid-19-issuing-emergency-use-authorization-first-covid-19.](https://www.fda.gov/news-events/press-announcements/fda-takes-key-action-fight-against-covid-19-issuing-emergency-use-authorization-first-covid-19)
- 318 10. US Food & Drug Administration. FDA takes additional action in fight against COVID-19
319 by issuing emergency use authorization for second COVID-19 vaccine.
320 [https://www.fda.gov/news-events/press-announcements/fda-takes-additional-action-fight-](https://www.fda.gov/news-events/press-announcements/fda-takes-additional-action-fight-against-covid-19-issuing-emergency-use-authorization-second-covid)
321 [against-covid-19-issuing-emergency-use-authorization-second-covid.](https://www.fda.gov/news-events/press-announcements/fda-takes-additional-action-fight-against-covid-19-issuing-emergency-use-authorization-second-covid)
- 322 11. US Food & Drug Administration. FDA issues emergency use authorization for third
323 COVID-19 vaccine. [https://www.fda.gov/news-events/press-announcements/fda-issues-](https://www.fda.gov/news-events/press-announcements/fda-issues-emergency-use-authorization-third-covid-19-vaccine)
324 [emergency-use-authorization-third-covid-19-vaccine.](https://www.fda.gov/news-events/press-announcements/fda-issues-emergency-use-authorization-third-covid-19-vaccine)
- 325 12. Stahlman S, Hiban K, Mahaney H, Ford S. Incident COVID-19 infections, active and
326 reserve components, 1 January 2020-31 August 2021. *MSMR*. 2021;28(12):14-21.
327 Accessed October 22, 2023. [https://health.mil/News/Articles/2021/12/01/Incident-Cov-](https://health.mil/News/Articles/2021/12/01/Incident-Cov-MSMR)
328 [MSMR](https://health.mil/News/Articles/2021/12/01/Incident-Cov-MSMR)
- 329 13. Losey S. Biden orders military to move toward mandatory COVID vaccine.
330 [https://www.military.com/daily-news/2021/07/29/biden-orders-military-move-toward-](https://www.military.com/daily-news/2021/07/29/biden-orders-military-move-toward-mandatory-covid-vaccine.html)
331 [mandatory-covid-vaccine.html.](https://www.military.com/daily-news/2021/07/29/biden-orders-military-move-toward-mandatory-covid-vaccine.html)
- 332 14. US Food & Drug Administration. FDA approves first COVID-19 vaccine.
333 [https://www.fda.gov/news-events/press-announcements/fda-approves-first-covid-19-](https://www.fda.gov/news-events/press-announcements/fda-approves-first-covid-19-vaccine)
334 [vaccine.](https://www.fda.gov/news-events/press-announcements/fda-approves-first-covid-19-vaccine)

- 335 15. Vergun D. Secretary of Defense mandates COVID-19 vaccinations for Service members.
336 US Department of Defense News. Published August 25, 2021. Accessed January 28,
337 2024. [https://www.defense.gov/News/News-Stories/Article/Article/2746111/secretary-of-](https://www.defense.gov/News/News-Stories/Article/Article/2746111/secretary-of-defense-mandates-covid-19-vaccinations-for-service-members/)
338 [defense-mandates-covid-19-vaccinations-for-service-members/](https://www.defense.gov/News/News-Stories/Article/Article/2746111/secretary-of-defense-mandates-covid-19-vaccinations-for-service-members/)
- 339 16. US Food & Drug Administration. FDA authorizes booster dose of Pfizer-BioNTech
340 COVID-19 vaccine for certain populations. [https://www.fda.gov/news-events/press-](https://www.fda.gov/news-events/press-announcements/fda-authorizes-booster-dose-pfizer-biontech-covid-19-vaccine-certain-populations)
341 [announcements/fda-authorizes-booster-dose-pfizer-biontech-covid-19-vaccine-certain-](https://www.fda.gov/news-events/press-announcements/fda-authorizes-booster-dose-pfizer-biontech-covid-19-vaccine-certain-populations)
342 [populations.](https://www.fda.gov/news-events/press-announcements/fda-authorizes-booster-dose-pfizer-biontech-covid-19-vaccine-certain-populations)
- 343 17. Theis SR, Li PC, Kelly D, et al. Perceptions and concerns regarding COVID-19
344 vaccination in a military base population. *Mil Med.* 2021;187(Special Issue 13):e1503-
345 e1508.
- 346 18. Higginson JD, Tumin D, Kuehhas TC, et al. COVID-19 vaccine hesitancy among
347 deployed personnel in a joint environment. *Mil Med.* 2023;188(1-2):e32-e36.
- 348 19. Nguyen KH, Mansfield KA, Xie CY, Corlin L, Niska RW. COVID-19 adult, childhood,
349 and adolescent vaccination coverage among military and civilian families, United States.
350 *Mil Med.* 2023;188(7-8):e2651-e2660.
- 351 20. US Centers for Disease Control and Prevention. COVID Data Tracker: COVID-19
352 vaccinations in the United States. [https://covid.cdc.gov/covid-data-](https://covid.cdc.gov/covid-data-tracker/#vaccinations_vacc-people-booster-percent-pop5)
353 [tracker/#vaccinations_vacc-people-booster-percent-pop5.](https://covid.cdc.gov/covid-data-tracker/#vaccinations_vacc-people-booster-percent-pop5)
- 354 21. Jones B, Kiley J. The changing geography of COVID-19 in the U.S. Pew Research
355 Center. Published December 8, 2020. Accessed April 23, 2024.
356 <https://www.pewresearch.org/politics/wp->

- 357 content/uploads/sites/4/2020/12/PP_2020.12.08_COVID-19-Deaths-Geography_Data-
358 Essay.pdf
- 359 22. Zhang S, Liu L, Meng Q, Zhang Y, Yahg H, Xu G. Spatiotemporal patterns of the
360 Omicron wave of COVID-19 in the United States. *Trop Med Infect Dis.* 2023;8(7):349.
- 361 23. Jones B. The changing political geography of COVID-19 over the last two years. Pew
362 Research Center. Published March 3, 2022. Accessed April 23, 2024.
363 [https://www.pewresearch.org/politics/2022/03/03/the-changing-political-geography-of-](https://www.pewresearch.org/politics/2022/03/03/the-changing-political-geography-of-covid-19-over-the-last-two-years/)
364 [covid-19-over-the-last-two-years/](https://www.pewresearch.org/politics/2022/03/03/the-changing-political-geography-of-covid-19-over-the-last-two-years/)
- 365 24. Centers for Disease Control and Prevention. Trends in number of COVID-19 vaccinations
366 in the US. Published May 11, 2023. Accessed January 28, 2024.
367 <https://covid.cdc.gov/covid-data-tracker/#vaccination-trends>
- 368 25. Hodcroft EB. CoVariants: SARS-CoV-2 mutations and variants of interest. Published
369 2021. Accessed January 28, 2024. <https://covariants.org/>
- 370 26. Centers for Disease Control and Prevention. Ending isolation and precautions for people
371 with COVID-19: Interim guidance. Published August 22, 2023. Accessed January 28,
372 2024. [https://www.cdc.gov/coronavirus/2019-ncov/hcp/duration-](https://www.cdc.gov/coronavirus/2019-ncov/hcp/duration-isolation.html#anchor_1631644826603)
373 [isolation.html#anchor_1631644826603](https://www.cdc.gov/coronavirus/2019-ncov/hcp/duration-isolation.html#anchor_1631644826603)
- 374 27. Centers for Disease Control and Prevention. Use of COVID-19 vaccines in the United
375 States: Interim clinical considerations. Published April 4, 2024. Accessed April 11, 2024.
376 <https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html>

- 377 28. Kaufman E, Lieberman O. US military branches set deadline for members to be
378 vaccinated against Covid-19. CNN. Published September 14, 2021. Accessed January 28,
379 2024. <https://www.cnn.com/2021/09/14/politics/us-military-sets-vaccine-dates/index.html>
- 380 29. Bonner KE, Vashist K, Abad NS, et al. Behavioral and social drivers of COVID-19
381 vaccination in the United States, August-November 2021. *Am J Prev Med*.
382 2023;64(6):865-876.
- 383 30. Santibanez TA, Singleton JA, Black CL, et al. Sociodemographic factors associated with
384 receipt of COVID-19 vaccination and intent to definitely get vaccinated, adults aged ≥ 18
385 years - Household Pulse Survey, United States, April 28-May 10, 2021. *CDC*
386 *AdultVaxView*. Published online June 15, 2021. Accessed January 28, 2024.
387 [https://www.cdc.gov/vaccines/imz-managers/coverage/adultvaxview/pubs-](https://www.cdc.gov/vaccines/imz-managers/coverage/adultvaxview/pubs-resources/sociodemographic-factors-covid19-vaccination.html#print)
388 [resources/sociodemographic-factors-covid19-vaccination.html#print](https://www.cdc.gov/vaccines/imz-managers/coverage/adultvaxview/pubs-resources/sociodemographic-factors-covid19-vaccination.html#print)
- 389 31. Roberts-McCarthy E, Buck PO, Smith-Ray RL, et al. Factors associated with receipt of
390 mRNA-1273 vaccine at a United States national retail pharmacy during the COVID-19
391 pandemic. *Vaccine*. 2023;41(29):4257-4266.
- 392 32. Cameron-Blake E, Tatlow H, Andretti B, et al. A panel dataset of COVID-19 policies in
393 185 countries. *Nat Hum Behav*. 2023;7:1402-1413.
- 394 33. Stanley-Becker I, Sun LH. "Pixie dust": Why some vaccine sits on shelves while
395 shortages intensify nationwide. *Washington Post*.
396 <https://www.washingtonpost.com/health/2021/01/21/vaccine-rollout-states-shortages/>.
397 Published January 21, 2021. Accessed January 28, 2024.

- 398 34. Liu K, Lou Y. Optimizing COVID-19 vaccination programs during vaccine shortages.
399 *Infect Dis Model.* 2022;7(1):286-298.
- 400 35. US Department of Health and Human Services. Secretarial directive on eligibility to
401 receive particular COVID-19 vaccine boosters. Published September 25, 2021. Accessed
402 July 8, 2024. [https://www.hhs.gov/sites/default/files/secretarial-directive-eligibility-covid-](https://www.hhs.gov/sites/default/files/secretarial-directive-eligibility-covid-19-vaccine-boosters.pdf)
403 [19-vaccine-boosters.pdf](https://www.hhs.gov/sites/default/files/secretarial-directive-eligibility-covid-19-vaccine-boosters.pdf)
- 404

Figure titles and legends

Figure 1. Monthly frequency of COVID-19 vaccine initiation

Table 1. Vaccine status, overall and in select states of residence

	All	California	Texas	Virginia	North Carolina	Georgia	Florida	Washington	P ^a
	N=1,779,466	N=213,128	N=162,709	N=146,939	N=124,573	N=84,380	N=83,156	N=76,683	
Vaccine history									<0.0001
Complete primary series, ≥1 booster	415,359 (23.3%)	40,689 (19.1%)	30,439 (18.7%)	38,632 (26.3%)	16,341 (13.1%)	12,957 (15.4%)	17,822 (21.4%)	17,678 (23.1%)	
Complete primary series, no booster	1,082,882 (60.9%)	139,186 (65.3%)	103,903 (63.9%)	93,209 (63.4%)	87,201 (70.0%)	55,906 (66.3%)	57,223 (68.8%)	48,164 (62.8%)	
Incomplete primary series	96,707 (5.4%)	8,534 (4.0%)	11,294 (6.9%)	2,838 (1.9%)	3,483 (2.8%)	4,882 (5.8%)	2,076 (2.5%)	3,132 (4.1%)	
No record of vaccination	184,518 (10.4%)	24,719 (11.6%)	17,073 (10.5%)	12,260 (8.3%)	17,548 (14.1%)	10,635 (12.6%)	6,035 (7.3%)	7,709 (10.1%)	
ADSMs who initiated a primary series ^b	N=1,594,948	N=188,409	N=145,636	N=134,679	N=107,025	N=73,745	N=77,121	N=68,974	
Primary series initiation timing ^c									<0.0001
Pre-mandate	1,230,623 (77.2%)	147,271 (78.2%)	108,818 (74.7%)	108,256 (80.4%)	75,147 (70.2%)	55,405 (75.1%)	56,734 (73.6%)	58,248 (84.5%)	
Post-mandate	364,325 (22.8%)	41,138 (21.8%)	36,818 (25.3%)	26,423 (19.6%)	31,878 (29.8%)	18,340 (24.9%)	20,387 (26.4%)	10,726 (15.6%)	
ADSMs who completed a two-dose primary series ^d	N=1,444,775	N=171,978	N=131,004	N=124,257	N=98,234	N=66,499	N=70,350	N=60,715	
Primary series completion timing ^e									<0.0001
Recommended	1,389,085 (96.2%)	165,245 (96.1%)	124,558 (95.1%)	120,944 (97.3%)	94,342 (96.0%)	63,816 (96.0%)	68,325 (97.1%)	60,715 (97.0%)	
Late	55,690 (3.9%)	6,733 (3.9%)	6,446 (4.9%)	3,313 (2.7%)	3,892 (4.0%)	2,683 (4.0%)	2,025 (2.9%)	1,862 (3.0%)	

ADSMs who received ≥ 1 booster dose following primary series completion	N=415,359	N=40,689	N=30,439	N=38,632	N=16,341	N=12,957	N=17,822	N=17,678	
Time from booster eligibility to receipt (days), median (IQR)	90 (68-120)	98 (71-125)	85 (59-115)	88 (63-118)	94 (63-127)	96 (70-125)	95 (70-120)	98 (72-121)	<0.0001

^aP values are for comparisons across the seven states listed in the table. ^bIncludes those who initiated either a one-dose or two-dose

primary series. ^cPre-mandate is defined as receipt prior to 23 August 2021, post-mandate is defined as on or after 23 August 2021.

^dIncludes only those who completed a two-dose primary series. ^ePrimary series completion in the recommended timing was defined as ≤ 56 days between the first and second dose; late is defined as >56 days between the first and second dose.

ADSMs, active duty Service members; IQR, interquartile range.

Table 2. Unadjusted odds of initiating the primary vaccine series prior to the DoD mandate, overall and in select states of residence^a

	All	California	Texas	Virginia	North Carolina	Georgia	Florida	Washington
	N=1,594,948	N=188,409	N=145,636	N=134,679	N=107,025	N=73,745	N=77,121	N=68,974
	Univariate OR (95% CI)	Univariate OR (95% CI)	Univariate OR (95% CI)	Univariate OR (95% CI)	Univariate OR (95% CI)	Univariate OR (95% CI)	Univariate OR (95% CI)	Univariate OR (95% CI)
Age								
17-49	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref
50-65	2.46 (2.38-2.54)	2.97 (2.55-3.47)	2.35 (2.13-2.60)	3.70 (3.19-4.28)	3.19 (2.70-3.78)	1.51 (1.32-1.72)	3.14 (2.66-3.71)	1.75 (1.39-2.21)
Sex								
Male	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref
Female	1.04 (1.03-1.05)	1.16 (1.13-1.20)	1.00 (0.97-1.03)	0.94 (0.91-0.97)	1.20 (1.16-1.26)	0.91 (0.87-0.96)	1.02 (0.98-1.06)	0.89 (0.84-0.93)
Race								
American Indian or Alaska Native	1.06 (1.02-1.10)	1.13 (1.03-1.24)	0.99 (0.87-1.12)	1.00 (0.89-1.13)	1.08 (0.94-1.25)	1.18 (0.96-1.45)	1.12 (0.96-1.31)	1.00 (0.84-1.20)
Asian or Pacific Islander	2.02 (1.98-2.05)	2.17 (2.06-2.28)	1.97 (1.86-2.09)	1.75 (1.63-1.89)	1.83 (1.70-1.97)	1.64 (1.50-1.80)	1.79 (1.63-1.96)	1.69 (1.54-1.84)
Black or African American	0.75 (0.74-0.76)	0.85 (0.82-0.87)	0.75 (0.73-0.78)	0.67 (0.65-0.69)	0.89 (0.86-0.92)	0.66 (0.64-0.69)	0.68 (0.66-0.71)	0.67 (0.63-0.70)
White	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref
Other	1.34 (1.32-1.37)	1.56 (1.48-1.63)	1.03 (0.67-1.10)	1.09 (1.03-1.14)	1.20 (1.10-1.31)	0.96 (0.87-1.07)	1.31 (1.23-1.40)	1.10 (1.00-1.21)
Hispanic Ethnicity								
Yes	1.03 (1.02-1.04)	0.86 (0.84-0.88)	1.10 (1.07-1.13)	1.01 (0.97-1.05)	0.96 (0.93-0.99)	1.10 (1.05-1.16)	1.02 (0.97-1.06)	1.07 (1.02-1.14)
No	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref

Branch of Service								
Air Force	0.88 (0.87-0.89)	1.02 (0.97-1.07)	0.66 (0.64-0.67)	1.16 (1.20-1.23)	0.79 (0.46-0.52)	0.91 (0.87-0.96)	0.93 (0.89-0.98)	0.43 (0.41-0.56)
Army	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref
Coast Guard	1.54 (1.50-1.58)	2.14 (1.95-2.35)	1.05 (0.93-1.17)	1.93 (1.76-2.12)	0.72 (0.64-0.81)	1.22 (0.99-1.52)	1.83 (0.69-1.99)	1.25 (1.08-1.45)
Marine Corps	0.58 (0.57-0.59)	0.65 (0.62-0.68)	0.69 (0.64-0.74)	0.79 (0.75-0.83)	0.30 (0.30-0.31)	0.71 (0.63-0.79)	0.91 (0.85-0.98)	0.57 (0.49-0.67)
Navy	1.54 (1.52-1.55)	1.87 (1.80-1.96)	0.92 (0.87-0.97)	1.42 (1.37-1.47)	0.86 (0.80-0.93)	1.68 (1.58-1.80)	1.67 (1.59-1.75)	1.38 (1.32-1.45)
Rank								
Enlisted	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref
Officer	4.28 (4.22-4.35)	5.32 (5.02-5.63)	3.94 (3.76-4.13)	4.41 (4.17-4.65)	5.59 (5.25-5.95)	3.01 (2.83-3.20)	4.67 (4.41-4.94)	3.89 (3.54-4.28)
Warrant Officer	2.03 (1.96-2.10)	2.61 (2.23-3.06)	1.81 (1.65-1.99)	2.41 (2.08-2.78)	2.52 (2.23-2.86)	2.01 (1.73-2.32)	2.76 (2.23-3.41)	1.98 (1.61-2.45)
COVID infection prior to initiating primary series								
Lab confirmed	0.55 (0.54-0.55)	0.57 (0.55-0.59)	0.69 (0.66-0.72)	0.58 (0.56-0.61)	0.51 (0.49-0.53)	0.56 (0.53-0.58)	0.49 (0.57-0.52)	0.43 (0.40-0.46)
ICD-10-CM defined	0.51 (0.50-0.52)	0.57 (0.54-0.61)	0.71 (0.68-0.74)	0.42 (0.39-0.45)	0.72 (0.67-0.76)	0.59 (0.54-0.63)	0.34 (0.32-0.36)	0.40 (0.36-0.44)
No	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref

Bold text indicates a significant difference from the reference category at $P < 0.05$.

OR, odds ratio; CI, confidence interval; Ref, reference group.

Table 3. Unadjusted difference in the mean days between booster eligibility and receipt, overall and in select states of residence

	All	California	Texas	Virginia	North Carolina	Georgia	Florida	Washington
	N=415,359	N=40,689	N=30,439	N=38,632	N=16,341	N=12,957	N=17,822	N=17,678
Age								
17-49	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref
50-65	-18.78 (-19.59, -17.96)	-18.46 (-21.73, -15.18)	-11.85 (-14.57, -9.14)	-25.88 (-28.98, -22.79)	-18.00 (-22.71, -13.28)	-13.78 (-18.21, -9.36)	-18.05 (-22.35, -13.75)	-23.52 (-28.53, -18.50)
Sex								
Male	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref
Female	-5.93 (-6.33, -5.53)	-3.92 (-5.18, -2.66)	-5.98 (-7.40, -4.56)	-6.99 (-8.56, -5.41)	-5.27 (-7.66, -2.88)	-5.68 (-8.13, -3.22)	-5.25 (-7.30, -3.21)	-5.93 (-7.87, -3.98)
Race								
American Indian or Alaska Native	4.23 (2.58, 5.87)	4.95 (0.72, 9.17)	6.17 (-0.65, 13.00)	3.50 (-2.36, 9.36)	-0.69 (-9.89, 8.50)	7.00 (-4.43, 18.44)	4.33 (-3.71, 12.28)	6.28 (-0.22, 12.77)
Asian or Pacific Islander	-0.27 (-0.52, 0.32)	0.82 (-2.28, 0.93)	-1.06 (-3.12, 1.00)	-1.12 (-3.70, 1.47)	1.45 (-2.01, 4.91)	-4.57 (-8.41, -0.72)	-0.74 (-4.31, 2.84)	1.91 (-0.54, 4.36)
Black or African American	-0.25 (-0.72, 0.22)	0.51 (-1.05, 2.07)	-1.63 (-3.22, -0.03)	0.90 (-0.84, 2.63)	0.58 (-1.92, 3.08)	-5.49 (-7.94, -3.04)	-0.23 (-0.61, 2.16)	4.67 (2.27, 7.07)
White	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref
Other	-0.81 (-1.47, -0.16)	0.52 (-1.25, 2.30)	-6.55 (-9.41, -3.68)	2.75 (0.35, 5.14)	-1.54 (-6.18, 3.10)	1.97 (-2.80, 6.74)	-0.51 (-3.48, 2.46)	3.21 (0.09, 6.32)
Hispanic Ethnicity								
Yes	4.20 (3.76, 4.65)	3.21 (1.95, 4.46)	3.36 (1.89, 4.82)	5.19 (3.32, 7.06)	4.77 (3.38, 7.16)	3.54 (0.83, 6.25)	1.40 (-0.87, 3.66)	5.72 (3.65, 7.80)
No	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref
Branch of Service								
Air Force	0.69 (0.28, 1.10)	12.04 (9.95, 14.14)	-8.08 (-9.42, -6.73)	1.25 (-1.48, 3.97)	-0.02 (-3.28, 3.25)	2.70 (0.22, 5.19)	6.04 (3.00, 9.08)	0.29 (-2.24, 2.82)
Army	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref

Coast Guard	-6.72 (-7.73, -5.71)	7.66 (4.75, 10.57)	1.60 (-4.54, 7.74)	0.73 (-3.20, 4.67)	-13.00 (-19.41, -6.59)	-11.53 (-23.78, 0.71)	11.23 (6.59, 15.86)	-24.32 (-29.31, -19.33)
Marine Corps	18.21 (17.51, 18.91)	30.08 (27.96, 32.20)	0.91 (-4.86, 6.68)	30.45 (27.14, 33.76)	3.96 (1.97, 5.95)	3.95 (-5.93, 13.82)	6.70 (1.04, 12.34)	24.95 (9.64, 40.26)
Navy	7.74 (7.33, 8.16)	23.22 (21.36, 25.07)	0.01 (-2.69, 2.70)	18.76 (16.90, 20.62)	-3.43 (-6.77, -0.09)	21.58 (18.92, 24.23)	11.25 (8.32, 14.18)	6.62 (5.00, 8.25)
Rank								
Enlisted	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref
Officer	-16.13 (-16.49, -15.78)	-15.24 (-16.39, -14.10)	-12.35 (-13.64, -11.07)	-24.25 (-25.66, -22.84)	-11.23 (-13.12, -9.35)	-9.17 (-11.27, -7.08)	-12.95 (-14.70, 11.21)	-17.51 (-19.23, -15.79)
Warrant Officer	-7.86 (-9.01, -6.71)	-9.22 (-13.59, -4.86)	-2.17 (-5.82, 1.48)	-15.38 (-20.03, -10.74)	-6.04 (-11.22, -0.86)	-4.61 (-10.14, 0.93)	-4.38 (-11.78, 3.01)	-7.98 (-13.22, -2.75)
COVID infection between primary series and booster								
Lab confirmed	40.72 (40.07, 41.36)	37.89 (35.85, 39.93)	40.03 (37.83, 42.23)	47.32 (44.08, 50.55)	40.68 (37.67, 43.69)	39.35 (35.75, 42.96)	45.78 (42.20, 49.15)	34.38 (31.47, 37.29)
ICD-10-CM defined	22.49 (21.61, 23.37)	22.98 (19.64, 26.32)	16.93 (13.84, 20.03)	29.67 (26.17, 33.18)	20.29 (14.93, 25.65)	23.71 (18.40, 29.03)	30.83 (27.05, 34.61)	25.17 (20.91, 29.44)
No	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref

Bold text indicates a significant difference from the reference category at P<0.05.

Ref, reference group.

Active duty Service members receiving the first COVID-19 primary series dose per month

